In August 2022, the European Medicines Agency published the revised EU GMP Annex 1 on the manufacture of sterile medicinal products. The revision introduced one of the most significant documentation requirements the industry had seen in years: every sterile manufacturing site must develop and maintain a documented, risk-based Contamination Control Strategy (CCS). The requirement was clear. The path to meeting it was not. Most sites reached for what they knew: Word documents,

Fragrance sells product, but it also drives some of the most complex labelling and formulation work you'll do in 2025 and beyond. Europe has expanded the list of fragrance allergens that must be named on labels when present above set thresholds, Great Britain hasn't (yet) mirrored those changes, and the U.S. is moving toward its own disclosure rule under MoCRA. Read on for a clear, practical path through the moving parts so you can plan reformulation, labelling, and artwork u

Environmental monitoring trends often look compliant until challenged. Internally, data may sit within defined alert and action limits. Deviations are opened when thresholds are crossed. Monthly review forums conclude that the cleanroom remains in control. From a governance standpoint, this appears disciplined. Inspection scrutiny often reframes that narrative entirely. What appears compliant in isolation can signal systemic weakness when assessed against regulatory expectati